NeoGenomics, Inc. (NEO) 2026 Q2 法說會逐字稿

內容摘要

  1. 摘要
    • Q2 營收達 2.017 億美元,年增 11%,優於原先 9% 的成長指引;臨床業務營收年增 14%,NGS 營收年增 26%,AUP(平均單價)年增 12%,檢測量年增 2%
    • 上修 2026 年全年營收指引至 8.02-8.06 億美元(原為 7.97-8.03 億),NGS 業務全年成長預期由低 20% 上修至中 20%;同時上修全年 EBITDA 指引至 5,600-5,800 萬美元
    • 盤後市場反應未提及,同業對比資訊亦未揭露
  2. 成長動能 & 風險
    • 成長動能:
      • NGS(次世代定序)業務持續高成長,Q2 年增 26%,大型 NGS panel 年增超過 20%,五大 NGS 產品年增 30%
      • 新產品(PanTracer 家族、RaDaR ST)切入療法選擇與 MRD 市場,帶動整體 NGS 業務與高價值檢測占比提升
      • Lab of the Future 計畫推動自動化、數位病理、儀器升級等,帶動毛利率擴張(Q2 毛利率提升 260bps)
      • 商業團隊擴編與組織重整,分為腫瘤與病理兩大生態系,提升執行力與滲透率
      • AUP 成長動能來自高價值檢測組合轉換與 RCM(收入循環管理)議價提升,仍有進一步提升空間
    • 風險:
      • 非臨床(Pharma)業務持續下滑,Q2 年減 26%,全年預期下修,短期內難以回復成長
      • RaDaR ST 等新產品未來營收貢獻高度依賴醫療保險(Medicare/MolDX)與商業保險給付進展
      • 高量低價合約退出造成短期檢測量成長壓力,Q3 將是最困難的比較基期
      • 整體 G&A(管理費用)仍高於同業,需持續推動效率提升
  3. 核心 KPI / 事業群
    • 總營收:Q2 年增 11%,達 2.017 億美元
    • 臨床業務營收:Q2 年增 14%,AUP 年增 12%,檢測量年增 2%
    • NGS 營收:Q2 年增 26%,佔臨床營收三分之一,NGS 檢測量年增 14%
    • 大型 NGS panel:Q2 年增超過 20%
    • 五大 NGS 產品:年增 30%,佔臨床營收 26%
    • 非臨床(Pharma)營收:Q2 年減 26%,佔總營收約 5%
    • ODS(Oncology Data Solutions)營收:Q2 年增 17%
    • 調整後毛利率:Q2 為 48.1%,年增 260bps
    • 調整後 EBITDA:Q2 為 1,440 萬美元,年增 36%,營收轉化率 19%
    • 商業團隊規模:Q3 預計超過 160 人,腫瘤與病理團隊各約 60+ 人
  4. 財務預測
    • 2026 年營收預估上修至 8.02-8.06 億美元(原為 7.97-8.03 億)
    • 2026 年毛利率預期提升 100-150 個基點
    • 2026 年調整後 EBITDA 指引上修至 5,600-5,800 萬美元(原為 5,500-5,700 萬)
    • Q2 資本支出 800 萬美元,主要用於 NovaSeq X 平台投資,未來 heme 檢測轉移預計 2027 年初完成
  5. 法人 Q&A
    • Q: NGS 業務下半年成長展望?指引是否保守?
      A: 上半年 NGS 業務表現強勁,Q1、Q2 皆年增 26%,因此全年成長指引由低 20% 上修至中 20%;大型 panel 與五大產品成長動能明確,組合轉換帶動 AUP,展望下半年持續樂觀。
    • Q: Pharma(非臨床)業務重要性與未來規劃?
      A: 臨床業務才是核心成長動能,Pharma 僅佔 5%,屬於機會型業務,主要作為新產品早期驗證與市場前哨,未來不會大幅投資,但會維持以利臨床產品研發與市場洞察。
    • Q: AUP(平均單價)成長可持續性?未來成長動能?
      A: AUP 成長來自高價值檢測組合轉換與 RCM 議價提升,NGS 量增與合約價格提升仍有空間,預期 Q3、Q4 仍以 AUP 成長為主,2027 年起隨著高量低價合約影響消退,檢測量成長將回升至中個位數,AUP 成長則趨緩。
    • Q: RaDaR ST 新適應症進度與市場機會?TAM 假設有無變動?
      A: 目前已取得兩項適應症給付,第三項已送審,預期年底前再獲兩項給付,2027 年上半年第三項有望通過。若五項皆獲批,TAM 可達 40%,較現有大幅提升,TAM 假設未變。
    • Q: NovaSeq X 平台轉換對 CapEx 與毛利率影響?
      A: Q2 投資 800 萬美元於 NovaSeq X,已完成 liquid 檢測轉換,heme 檢測預計 2027 年初完成。由於 liquid 佔比小,短期毛利率貢獻有限,heme 完成後 2027 年下半年起毛利率將有明顯提升。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good afternoon and welcome to the NeoGenomics second-quarter 2026 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded.

    下午好,歡迎參加 NeoGenomics 2026 年第二季財務業績電話會議。(接線員指示) 請注意,今天的會議將被錄音。

  • I will now turn the call over to Abhishek Jain, Chief Financial Officer.

    現在我將把電話交給財務長 Abhishek Jain。

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Before we begin, I would like to introduce Andrew Brackmann, who recently joined NeoGenomics as our new Vice President of Investor Relations. Andrew spent nearly a decade in sell-side equity research covering the diagnostic sector. He also covered NeoGenomics directly, giving him a deep understanding of both the company and its competitive landscape.

    在開始之前,我想先介紹 Andrew Brackmann,他近期加入 NeoGenomics,擔任我們新的投資人關係副總裁。Andrew 在賣方股票研究領域近十年,主要覆蓋診斷產業。他也曾直接覆蓋 NeoGenomics,因此對公司及其競爭格局都有深入的理解。

  • Beyond his analytical depth, Andrew is known for building genuine, long-term relationships with the people he works with. We're excited to have Andrew on board to lead and shape our Investor Relations strategy and deepen our relationships across the investor and analyst community.

    除了深厚的分析能力之外,Andrew 也以能與合作夥伴建立真誠、長期的關係而聞名。我們很高興 Andrew 加入團隊,領導並塑造我們的投資人關係策略,並深化我們與投資人及分析師社群的關係。

  • Now let me turn the call over to Andrew to get us started. Andrew.

    現在讓我把電話交給 Andrew 來為我們開場。Andrew。

  • Andrew Brackmann - Vice President of Investor Relations

    Andrew Brackmann - Vice President of Investor Relations

  • Thank you, Abhishek, and good afternoon, everyone. I am excited to be joining NeoGenomics in this role. Having covered the stock for the last eight years during my time at William Blair, I have been inspired by the team's ability to leverage its well-earned channel strength and provide new and holistic testing solutions for patients.

    謝謝你,Abhishek,各位下午好。我很高興能以這個角色加入 NeoGenomics。在 William Blair 任職期間,我在過去八年覆蓋這檔股票;團隊能善用多年建立的通路優勢,並為病患提供全新且更全面的檢測解決方案,令我深受啟發。

  • I see this strategy as driving durable, profitable growth that betters Neo over the long-term for all stakeholders. With recent new product launches, further expanding growth opportunities across large end markets, now is a great time to join the company.

    我認為這項策略將推動具韌性且可獲利的成長,長期而言能讓 Neo 對所有利害關係人更好。隨著近期新產品上市,並進一步擴大在大型終端市場的成長機會,現在正是加入公司的好時機。

  • In this role, it is my goal to partner with the investment community in an ongoing effort to better articulate and communicate our strategy and differentiation. This is something I believe to be a real opportunity to improve upon based on my experience on the sell side. I'm confident my skill set and experience across financial markets will be helpful in this regard.

    在這個職務上,我的目標是與投資社群合作,持續更清楚地闡述並傳達我們的策略與差異化優勢。根據我在賣方的經驗,我相信這是一個確實可以改進的機會。我有信心,我在金融市場的技能組合與經驗將在這方面有所助益。

  • Now let's get into today's call. Representing NeoGenomics here today are Tony Zook, Chief Executive Officer; Warren Stone, President and Chief Commercial Officer; and Abhishek Jain, Chief Financial Officer. Additional members of the management team will be available for the Q&A portion of our call. This call is being simultaneously webcast.

    現在我們進入今天的會議內容。今天代表 NeoGenomics 出席的有:執行長 Tony Zook;總裁兼商務長 Warren Stone;以及財務長 Abhishek Jain。管理團隊的其他成員也將在問答環節提供支援。本次電話會議也將同步進行網路直播。

  • During this call, we will make forward-looking statements regarding our future financial and business performance, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, estimated market size and position, and objectives of management and financial guidance.

    在本次電話會議中,我們將就未來的財務與業務表現、規劃中的未來營運及其在時程與績效方面的相關預期、未來財務狀況、未來營收、成長潛力與預期成長動能、預估成本與資本支出、前景與計畫、估計市場規模與市場地位,以及管理階層目標與財務指引等作出前瞻性陳述。

  • We caution you that the actual events or results could differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements made during the call speak only as of the original date of this call, and we undertake no obligation to update or revise any of these statements.

    我們提醒您,實際事件或結果可能與前瞻性陳述中明示或暗示的內容存在重大差異。本次電話會議中的前瞻性陳述僅截至本次會議原始日期有效,我們不承擔更新或修訂任何此類陳述的義務。

  • Please refer to the information disclosed on the Safe Harbor Statement slide in the deck posted on our website, as well as the information under the heading Risk Factors and our most recent Forms 10-K, 10-Q, and 8-K that were filed with the SEC to identify important risks or other factors that may cause our actual results to differ materially from the forward-looking statements. These documents can be found in the Investors section of our website or on the SEC's website.

    請參閱我們網站上所發布簡報中的「安全港聲明」投影片所揭露的資訊,以及我們最近向美國證券交易委員會(SEC)提交的 10-K、10-Q 與 8-K 表格中「風險因素」標題下的資訊,以識別可能導致實際結果與前瞻性陳述存在重大差異的重要風險或其他因素。這些文件可在我們網站的投資人專區或 SEC 網站上查閱。

  • During this call, we will also refer to certain non-GAAP financial measures that involve adjustments to GAAP results. The non-GAAP financial measures presented should not be considered an alternative to the financial measures required by GAAP, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies.

    在本次電話會議中,我們也將提及若干非 GAAP 財務衡量指標,這些指標包含對 GAAP 結果的調整。所呈現的非 GAAP 財務衡量指標不應被視為 GAAP 所要求財務衡量指標的替代,也不應被視為流動性衡量指標,且很可能無法與其他公司提供的非 GAAP 財務衡量指標相互比較。

  • Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measures in a table available in the press release we issued this afternoon and in the slide deck available in the Investors section of our website.

    本次電話會議中提及的任何非 GAAP 財務衡量指標,均已在我們今天下午發布的新聞稿以及我們網站投資人專區提供的簡報中,以表格方式與最直接可比的 GAAP 財務衡量指標進行調節。

  • I will now turn the call over to Tony.

    現在我將把電話交給 Tony。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Well, thank you, Andrew, and welcome to the team. We're very pleased to have you join us. And good afternoon, everyone. At NeoGenomics, our leading 25% market share across hematology diagnostics and therapy selection make us a trusted provider of oncology testing solutions for pathologists, oncologists, and patients.

    好的,謝謝你,Andrew,也歡迎加入團隊。我們非常高興你能加入。各位下午好。在 NeoGenomics,我們在血液腫瘤診斷與治療選擇領域擁有領先的 25% 市占率,使我們成為病理科醫師、腫瘤科醫師與病患信賴的腫瘤檢測解決方案供應商。

  • We're leveraging this leadership position as a trusted partner in hematology by expanding our menu of solid tumor testing offerings in the large, underpenetrated markets of therapy selection and MRD, where we've recently launched new products, expanding our PanTracer family and RaDaR ST. Our entry into these markets is driving growth across our entire NGS business while providing halo effects to the rest of our portfolio.

    我們正運用在血液腫瘤領域作為可信賴合作夥伴的領導地位,擴充我們在實體腫瘤檢測的產品組合,切入治療選擇與 MRD(微量殘存疾病)等龐大且滲透率仍低的市場;我們近期已推出新產品,擴展 PanTracer 產品家族與 RaDaR ST。我們進入這些市場正帶動整體 NGS 業務成長,同時也對我們其餘產品組合產生光環效應。

  • They're also helping to drive increases in our gross margin. In the second quarter, our strategy drove this intended effect, and we remain confident in our objective of driving durable and profitable growth over the near and long-term.

    它們也有助於推動我們毛利率的提升。在第二季,我們的策略產生了預期的效果;我們仍對在短期與長期推動具韌性且可獲利成長的目標充滿信心。

  • As it relates to the second quarter results, these reflect the consistency that investors have come to expect from this team. We're raising guidance because of these results, as well as the underlying clinical strength we're seeing in the back half of this year.

    就第二季業績而言,這些結果反映了投資人對本團隊一貫表現的期待。基於這些結果,以及我們在今年下半年看到的臨床動能,我們上調財測指引。

  • Total revenue in the quarter was $201.7 million, up 11% year over year and ahead of the 9% growth we guided to for the quarter. Our top-line performance continues to be driven by our clinical business, which grew by 14% in the quarter as AUP increased 12% and volumes exceeded our target and grew 2%.

    本季總營收為 2.017 億美元,年增 11%,高於我們對本季所給出的 9% 成長指引。我們的營收表現持續由臨床業務帶動;臨床業務本季成長 14%,其中 AUP 年增 12%,檢測量超出我們的目標並成長 2%。

  • Moreover, our growth in NGS is proving to be durable with revenue growing 26% year over year and again comprising one-third of our clinical revenue. The mix shift towards higher value testing continues, and we believe our NGS portfolio is well positioned to drive more predictable and profitable revenue growth in the future.

    此外,我們在 NGS 的成長證明具有韌性,營收年增 26%,且再次占我們臨床營收的三分之一。產品組合持續朝向更高價值的檢測項目轉移;我們相信,我們的 NGS 產品組合已具備良好定位,可在未來推動更可預測且更具獲利性的營收成長。

  • Alongside this growth, our go-to market approach continues to evolve as well. This quarter, we reorganized our commercial team into two dedicated ecosystems, one focused on oncology and one on pathology, sharpening accountability as we scale toward our next phase of growth. Warren will cover this in more detail shortly.

    在成長的同時,我們的市場進入策略也持續演進。本季我們將商務團隊重整為兩個專注的生態系:一個聚焦腫瘤科,另一個聚焦病理領域;在我們邁向下一階段成長的擴張過程中,這將強化責任歸屬。Warren 稍後會更詳細說明。

  • While the 14% growth in our clinical business is exceeding our expectations, our nonclinical business is falling short of expectations. In particular, our pharma business, which accounts for roughly 5% of total revenue, continues to face headwinds even as bookings increase.

    儘管我們臨床業務 14% 的成長超出預期,但我們的非臨床業務表現未達預期。特別是我們的藥廠(pharma)業務,約占總營收 5%,即使接單增加,仍持續面臨逆風。

  • The decline in pharma was slightly offset by 17% growth in our ODS business, but still not enough to offset the weakness for our entire nonclinical business. So we're adjusting expectations for pharma revenues for the full year. Abhishek will cover the specifics, but we're taking corrective actions and remain committed to returning to year-over-year growth for our entire nonclinical segment in 2027, as we've discussed in the past.

    藥廠業務的下滑部分被我們 ODS 業務 17% 的成長所抵銷,但仍不足以彌補整體非臨床業務的疲弱。因此,我們正在調整對全年藥廠營收的預期。Abhishek 將說明具體細節;我們正採取矯正措施,並仍致力於如過去所討論的,在 2027 年讓整體非臨床部門恢復年對年成長。

  • Turning to margins, we saw significant margin improvement this quarter as we anticipated. Adjusted gross margin expansion of 260 basis points year over year was driven primarily by strong AUP growth of 12%, as well as improvements from our Lab of the Future initiative, which spans across automation, digital pathology, and instrument upgrades, among other initiatives. Warren will discuss our Lab of the Future initiative in more detail momentarily.

    談到毛利率,我們如預期在本季看到顯著的毛利率改善。調整後毛利率年增擴張260個基點,主要由12%的AUP強勁成長所帶動,並受惠於我們「未來實驗室」(Lab of the Future)計畫帶來的改善;該計畫涵蓋自動化、數位病理、儀器升級等多項措施。Warren稍後將更詳細說明我們的未來實驗室計畫。

  • Beyond the gross margin expansion, we also maintained operating expenses discipline in the quarter, helping to drive 36% growth in our adjusted EBITDA.

    除了毛利率擴張之外,我們本季也維持營運費用的紀律,進而推動調整後EBITDA成長36%。

  • On the product front, this quarter was less about new launches and more about converting the launches we discussed last quarter into real commercial traction. Our PanTracer family and RaDaR ST together address a combined $33 billion market opportunity across therapy selection and MRD and round out a portfolio that spans the cancer care continuum from initial diagnosis through recurrence monitoring.

    在產品方面,本季較少著重新品上市,而是更聚焦於將我們上季討論的上市產品轉化為實際的商業動能。我們的PanTracer產品家族與RaDaR ST合計可涵蓋治療選擇與MRD領域約330億美元的市場機會,並完善我們橫跨癌症照護全流程的產品組合,從初始診斷一路延伸至復發監測。

  • Early feedback for these products is encouraging, and our expectations for these products in 2026 are unchanged, contributing modestly to revenue this year while driving pull-through in other areas of our portfolio.

    這些產品的早期回饋令人鼓舞,我們對其在2026年的預期維持不變;今年對營收的貢獻仍屬溫和,但將帶動我們產品組合其他領域的拉動效應(pull-through)。

  • This is something unique to NeoGenomics as we have the capabilities and menu that other pure-play NGS providers don't have. As we look ahead, we continue to see more meaningful contributions from these specific products over the coming years. This is especially true for RaDaR ST where reimbursement decisions will be key to driving future revenue.

    這是NeoGenomics獨有的優勢,因為我們具備其他純NGS業者所沒有的能力與檢測選單。展望未來,我們持續預期這些特定產品在未來數年將帶來更具實質性的貢獻。對RaDaR ST而言尤其如此,因為給付(reimbursement)決策將是推動未來營收的關鍵。

  • In the quarter, we submitted an additional RaDaR ST indication to MolDX and now have three pending submissions. If successful in achieving these reimbursement wins, as well as with commercial payers over the longer-term, these reimbursement wins will significantly improve our ability to drive revenue in this large market.

    本季我們向MolDX額外提交了一項RaDaR ST適應症,目前共有三項提交案仍在審查中。若能成功取得這些給付核准,並在更長期也獲得商業保險支付方的支持,這些給付成果將大幅提升我們在此龐大市場中推動營收的能力。

  • Beyond the commercial traction we're seeing across our portfolio, we continue to invest in the pipeline that will sustain our growth well beyond 2026. Notably, our next-generation whole genome sequencing MRD assay remains on track, and we expect to generate data for this assay in 2027 and be ready for a potential clinical launch in 2029.

    除了我們在整體產品組合上看到的商業動能之外,我們也持續投資於研發管線,以支撐2026年之後更長期的成長。值得一提的是,我們的次世代全基因組定序(WGS)MRD檢測仍按計畫推進,預期於2027年產出該檢測的數據,並在2029年具備潛在臨床上市的準備。

  • Our companion diagnostics capabilities were strengthened with the recent launch of PTEN, a new FDA-approved immunohistochemistry companion diagnostic for prostate cancer. This test, which is available stand-alone or as part of our PanTracer Pro offering, identifies patients who may be eligible for AstraZeneca's newly approved TRUQAP and allows us to reach into urologic oncology, a new setting for us.

    隨著近期推出PTEN,我們的伴隨診斷能力進一步強化;PTEN是一項新的FDA核准免疫組織化學(IHC)前列腺癌伴隨診斷。此檢測可單獨提供,或作為我們PanTracer Pro方案的一部分,用以辨識可能符合阿斯特捷利康(AstraZeneca)新近核准TRUQAP治療資格的患者,並使我們得以切入泌尿腫瘤學這一對我們而言的新場景。

  • For our pharma and biopharma partners, work continued in the second quarter with new biomarker data presented at ASCO, supporting our partners who are advancing ADCs, BiTEs, bispecifics, and targeted therapies. We're also developing a low sample input AML/MRD flow assay designed to deliver higher sensitivity and faster turnaround times across CLL, B-ALL, and multiple myeloma.

    針對我們的製藥與生物製藥合作夥伴,第二季持續推進相關工作,並在ASCO發表新的生物標記數據,支持合作夥伴推進ADC、BiTE、雙特異性抗體以及標靶治療。我們也正在開發一項低樣本輸入的AML/MRD流式檢測,旨在於CLL、B-ALL與多發性骨髓瘤等領域提供更高靈敏度與更快的報告週轉時間。

  • In sum, the second quarter builds on many of the favorable trends we saw in the first, steady top-line growth, expanding margins, and continued scientific and pipeline progress against our 2026 priorities. Perhaps more important is that we're delivering consistent results, which underpin our confidence in our updated guidance ranges.

    總結而言,第二季延續了我們在第一季看到的多項有利趨勢:營收穩健成長、利潤率擴張,以及在科學與研發管線方面持續取得進展,並對齊我們2026年的優先事項。或許更重要的是,我們正在交付一致且穩定的成果,這也支撐了我們對更新後財測區間的信心。

  • We remain in the early stages of penetrating the solid tumor therapy selection and MRD markets and the groundwork we're laying now in our science, our lab operations, and our product portfolio positions us well for the years ahead.

    我們在實體腫瘤治療選擇與MRD市場的滲透仍處於早期階段,而我們目前在科學、實驗室營運與產品組合上所奠定的基礎,將使我們在未來數年具備良好定位。

  • With that, I'll turn the call over to Warren who will provide more detail on how we continue to win in the community and on the progress of our commercial and operational initiatives this quarter.

    接下來我把電話會議交給Warren,他將更詳細說明我們如何持續在社區端取勝,以及本季商業與營運計畫的進展。

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Thank you, Tony, and good afternoon, everybody. I want to begin with a brief update on our commercial momentum before turning to the operational progress, including our Lab of the Future initiative that is supporting the launches that Tony just discussed.

    謝謝你,Tony,各位下午好。在談到營運進展之前,我想先簡要更新我們的商業動能,其中也包括支持Tony剛才提到之產品上市的「未來實驗室」計畫。

  • Our primary focus remains in the community setting, where approximately 80% of patients seek treatment. Community oncologists are guideline driven and focused on certainty. They choose partners that reduce friction and enable confident treatment decisions under real operational and time pressure.

    我們的主要重點仍在社區端場景,約有80%的患者在此尋求治療。社區腫瘤科醫師以臨床指引為依據,並重視確定性。他們會選擇能降低摩擦、並在實際營運與時間壓力下仍可做出有信心治療決策的合作夥伴。

  • This is precisely the value that NeoGenomics offers. That differentiation again delivered strong results in the second quarter. Clinical revenue grew 14% year over year with every test modality growing at or above market, led by NGS, which grew 26%.

    這正是NeoGenomics所提供的價值。這項差異化在第二季再次帶來強勁成果。臨床營收年增14%,各項檢測模式的成長皆達到或高於市場水準,其中以NGS領先,成長26%。

  • The five NGS products across hematology and solid tumor that we launched since 2023 and have consistently tracked continue to drive growth across the NGS portfolio, growing over 30% and now representing 26% of our total clinical revenue.

    自2023年以來我們在血液腫瘤與實體腫瘤領域推出並持續追蹤的五項NGS產品,持續帶動整體NGS產品組合成長,增幅超過30%,目前已占我們臨床總營收的26%。

  • Clinical volumes increased 2%, exceeding our expectations, while NGS volume was broad-based across both heme and solid tumor testing, growing 14%. Our large NGS panels grew well above 20% in the quarter through increased market penetration and continuous mix shift from our targeted gene panels to these larger NGS panels.

    臨床檢測量增加2%,高於我們預期;同時NGS檢測量在血液腫瘤與實體腫瘤檢測兩端皆呈現廣泛成長,增幅達14%。本季我們的大型NGS panel成長遠高於20%,主要來自市場滲透率提升,以及產品組合持續由標靶基因panel轉向這些更大型的NGS panel。

  • As Tony mentioned, our leadership position in heme continues to serve as a trusted foundation from which we are expanding adoption of our broader portfolio. This proven model, combining a broad test menu, fast and reliable turnaround times, deep payer coverage, and workflow integration is what differentiates us in the community.

    如Tony所提,我們在血液腫瘤(heme)領域的領導地位,持續作為值得信賴的基礎,讓我們得以擴大更廣泛產品組合的採用。這一經驗證的模式——結合廣泛的檢測選單、快速且可靠的報告週轉時間、深度的支付方覆蓋,以及工作流程整合——正是我們在社區端的差異化所在。

  • This activation of the initial Epic Aura integrations announced in April will strengthen our differentiation and has the potential to drive higher test adoption per site while supporting the rollout of our next generation capabilities, including the PanTracer family and MRD. We expect benefits from these integrations to begin in 2027. Combined, our broad portfolio of testing, leading market share in heme, and ability to remove friction from our customers are helping deliver the strong results I've just mentioned.

    四月宣布的初始Epic Aura整合如今開始啟用,將強化我們的差異化,並有機會在每個據點推動更高的檢測採用量,同時支持我們下一代能力的推廣,包括PanTracer產品家族與MRD。我們預期這些整合帶來的效益將自2027年開始顯現。綜合而言,我們廣泛的檢測產品組合、在血液腫瘤領域的領先市占,以及為客戶消除摩擦的能力,正協助交付我剛才提到的強勁成果。

  • They also lead to an industry-leading customer experience, as evidenced by our Net Promoter Score in the high 70s across both pathology and oncology. As one of our oncology customers put it, we deliver an excellent experience that they've come to trust completely.

    這些優勢也帶來業界領先的客戶體驗,從我們在病理與腫瘤兩個領域皆達到70多分高段的淨推薦值(NPS)即可見一斑。正如我們的一位腫瘤客戶所說,我們提供了他們完全信賴的卓越體驗。

  • A recent example illustrates our differentiation in practice. A Florida medical center and cancer institute sought to accelerate decision making for lung cancer patients, but faced workflow challenges coordinating blood collection at surgery with tissue-based diagnostic workups completed weeks later.

    近期的一個案例可具體說明我們在實務上的差異化。佛羅里達州一間醫療中心與癌症研究所希望加速肺癌患者的決策流程,但在工作流程上面臨挑戰:手術時的抽血採集需與數週後才完成的組織型診斷檢查協調配合。

  • Our field and customer support teams work with the hospital surgery, pathology, pulmonology, oncology teams to build an integrated workflow that allows for blood-based testing to begin while tissue is in transit, delivering comprehensive molecular insights in under 10 days from diagnosis and eliminating the need for additional patient visits or blood draws. Hospital lab managers described our coordination as critical to patient care.

    我們的前線與客戶支援團隊與醫院的外科、病理、肺科與腫瘤團隊合作,建立整合式工作流程,使得在組織樣本運送途中即可啟動血液檢測,並在確診後10天內提供全面的分子洞見,同時免除患者額外回診或再次抽血的需求。醫院實驗室管理人員形容我們的協調對病患照護至關重要。

  • Turning now to new products. With RaDaR ST, we currently have two indications that have received Medicare reimbursement through MolDX, HPV-negative head and neck cancer, and a subset of breast cancers.

    接著談新產品。就RaDaR ST而言,我們目前有兩項適應症已透過MolDX取得Medicare給付:HPV陰性的頭頸癌,以及部分乳癌亞群。

  • We previously submitted two additional indications to MolDX and during the second quarter submitted a third indication. If all five of these indications are approved, as we anticipate, we would have access to over 40% of the total addressable market for tumor-informed MRD testing.

    我們先前已向MolDX提交另外兩項適應症,並在第二季再提交第三項適應症。若這五項適應症皆如我們預期獲得核准,我們將可觸及腫瘤知情(tumor-informed)MRD檢測整體可服務市場(TAM)超過40%的份額。

  • While it remains early in the launch, early insights are encouraging. Roughly 30% of RaDaR ST orders included another test from Neo's menu. Two-thirds of orders are for indications we already have approved reimbursement for MolDX, and one-third of the orders from patients on Medicare are for indications we already have reimbursement in place.

    儘管目前仍處於上市初期,但初步洞察令人鼓舞。約有 30% 的 RaDaR ST 訂單同時包含 Neo 檢測選單中的另一項檢測。其中三分之二的訂單屬於我們已取得 MolDX 核准給付的適應症;而來自 Medicare 病患的訂單中,有三分之一亦屬於我們已建立給付的適應症。

  • On the scientific front, we continue to build the evidence base behind RaDaR ST, and at ASCO and ASDR this year, we presented new clinical data across a range of tumor types. This reinforces evidence supporting our current and future reimbursement submissions.

    在科學面上,我們持續累積 RaDaR ST 的證據基礎;在今年的 ASCO 與 ASDR,我們發表了涵蓋多種腫瘤類型的新臨床數據。這進一步強化了支持我們目前及未來給付申請所需的證據。

  • In our PanTracer portfolio, since securing MolDX reimbursement, our PanTracer LBx in early March, we have been focusing on driving adoption throughout the year. We continue to see strong physician interest in the coordinated workflow PanTracer Pro enables, combining comprehensive genomic profiles with IHC and auxiliary tests from a single sample and requisition.

    在我們的 PanTracer 產品組合方面,自取得 MolDX 給付後,我們於 3 月上旬推出 PanTracer LBx,並在全年持續聚焦推動採用。我們持續看到醫師對 PanTracer Pro 所提供的協同工作流程抱持高度興趣;該流程可在單一檢體與單一申請單下,結合全面性的基因體圖譜、IHC 與輔助檢測。

  • Turning to our commercial organization, we remain committed to expanding our clinical commercial organization as new products launch and gain momentum and additional RaDaR ST reimbursement approvals come through.

    談到我們的商業組織,隨著新產品上市並逐步累積動能,以及 RaDaR ST 取得更多給付核准,我們仍致力於擴大臨床商業團隊。

  • We remain on track to exceed 160 commercial representatives during the third quarter, and we'll continue to assess the size of our commercial organization over the coming years based on market penetration rates and reimbursement wins across products like RaDaR ST and therapy selection.

    我們仍按計畫在第三季將商業代表人數提升至超過 160 名;未來幾年,我們也將依據市場滲透率以及 RaDaR ST 與治療選擇等產品的給付進展,持續評估商業組織的規模。

  • With these recent commercial investments, we have achieved scale in our oncology sales specialist team, allowing us to optimize our structure and organize our commercial organization around two dedicated ecosystems, one for pathology and one for oncology, supported by aligned marketing, medical science liaison, and other teams. This sharper focus will enhance execution, strengthen accountability, and better position us to sustain growth across both businesses.

    透過近期的商業投資,我們的腫瘤銷售專家團隊已達到規模化,使我們得以優化組織架構,並將商業組織圍繞兩個專屬生態系統來運作:一個聚焦病理,另一個聚焦腫瘤,並由一致對齊的行銷、醫學科學聯絡(MSL)及其他團隊提供支援。更聚焦的策略將提升執行力、強化責任歸屬,並使我們更有利於在兩大業務上維持成長。

  • As Tony mentioned, the Lab of the Future initiative is a meaningful driver of margin expansion. This program spans six areas: digital pathology, AI-assisted lab automation, instrument platform upgrades, and NEO LIMS implementation, strategic procurements, and laboratory footprint optimization.

    如 Tony 所提,「未來實驗室」(Lab of the Future)計畫是推動毛利率擴張的重要動能。該計畫涵蓋六大領域:數位病理、AI 輔助的實驗室自動化、儀器平台升級與 NEO LIMS 導入、策略性採購,以及實驗室據點(footprint)最佳化。

  • This quarter, we closed two dry labs, optimized administrative footprints, further advanced volumes across our laboratory network, exited low-margin non-oncology business acquired with Pathline, and captured additional AI-driven automation efficiencies.

    本季我們關閉了兩座乾式實驗室(dry labs)、最佳化行政據點配置,並進一步提升我們實驗室網路的處理量;同時退出隨 Pathline 併購而來的低毛利非腫瘤業務,並取得更多由 AI 驅動的自動化效率提升。

  • We also completed the transition of PanTracer LBx as our first clinical assay to the NovaSeq X platform, an important milestone that we believe allows us to process liquid biopsy volumes with greater throughput, improve TAT, and lower per test cost as volume scale, supporting both our gross margin expansion goals and our ability to serve more patients. We expect continued efficiency gains from the Lab of the Future program to support gross margin expansion goals for the remainder of the year.

    我們也完成將 PanTracer LBx 作為首個臨床檢測項目轉移至 NovaSeq X 平台,這是一項重要里程碑;我們相信此舉可讓我們以更高的吞吐量處理液體活檢量、改善 TAT(周轉時間),並在規模放大時降低單次檢測成本,進而同時支持毛利率擴張目標與服務更多病患的能力。我們預期「未來實驗室」計畫在今年剩餘期間仍將帶來持續的效率提升,以支持毛利率擴張目標。

  • In summary, we're executing a clear strategy, winning the community with a broad and integrated portfolio by reducing friction and delivering actionable insights across the cancer care continuum from diagnosis to recurrence monitoring. Our ongoing investment in commercial expansion, EHR integration, and customer experience delivered durable growth, while our Lab of the Future initiative contributes to improved gross margin.

    總結而言,我們正執行清晰的策略:以廣泛且整合的產品組合贏得社區市場,透過降低摩擦並提供可採取行動的洞察,覆蓋癌症照護連續體中從診斷到復發監測的各個環節。我們持續投資於商業擴張、EHR 整合與客戶體驗,帶來具韌性的成長;同時,「未來實驗室」計畫也促進毛利率改善。

  • With that, I'll hand over to Abhishek to walk us through the financial results.

    接下來我把時間交給 Abhishek,由他帶領大家回顧財務結果。

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Thank you, Warren, and good afternoon, everyone. In my remarks today, I will discuss our second quarter financial results and our updated 2026 guidance.

    謝謝你,Warren,各位下午好。在今天的說明中,我將討論我們第二季的財務結果,以及更新後的 2026 年財測指引。

  • We reported total revenue of $201.7 million, up 11% year over year, which exceeded our prior guidance by approximately $4 million. Clinical revenue grew a strong 14% year over year, driven by a 2% increase in test volumes and a 12% increase in AUP.

    我們公布的總營收為 2.017 億美元,年增 11%,較先前指引高出約 400 萬美元。臨床營收年增強勁達 14%,主要由檢測量年增 2% 與 AUP 年增 12% 所帶動。

  • We are pleased to see the mix shift towards high-value testing continue to build, with NGS revenue growth of 26%, driven by volume growth of 14%. Also, the mix shift towards high-value testing remained a key contributor for AUP growth of 12% year over year. In addition, AUP benefited from continued work on RCM initiatives, including managed care pricing gains and pull-through improvement.

    我們很高興看到產品組合持續朝高價值檢測移轉;NGS 營收成長 26%,其中量的成長為 14%。此外,朝高價值檢測的組合移轉仍是 AUP 年增 12% 的關鍵貢獻因素。同時,AUP 也受惠於我們持續推動的 RCM(營收循環管理)計畫,包括商業保險(managed care)定價提升與拉動效應(pull-through)改善。

  • Turning to our nonclinical business. We reported revenue of $14.5 million, a decline of 15% year over year. Pharma revenue declined 26%, which was partially offset by 17% growth in our Oncology Data Solutions business. And while pharma revenue came below our expectations for Q2, we believe that we are near the bottom for this business.

    接著看我們的非臨床業務。我們的營收為 1,450 萬美元,年減 15%。製藥(Pharma)營收年減 26%,但部分被我們腫瘤數據解決方案(Oncology Data Solutions)業務 17% 的成長所抵銷。雖然第二季製藥營收低於我們預期,但我們認為該業務已接近谷底。

  • Adjusted gross margin for the second quarter was 48.1%, an expansion of approximately 260 basis points versus the prior year period. Adjusted gross profit increased by a healthy $14.5 million or 18% over the prior year to $96.9 million.

    第二季調整後毛利率為 48.1%,較去年同期擴張約 260 個基點。調整後毛利較去年同期健康成長 1,450 萬美元(年增 18%),達到 9,690 萬美元。

  • This expansion was driven by AUP growth, volume leverage, and Lab of the Future efficiencies. We also absorbed the impact of higher freight costs and fuel surcharges. Gross margin expansion remains a key focus area for us, and we are pleased to see that our efforts have started to yield results on this metric.

    此一擴張主要由 AUP 成長、量的槓桿效益,以及「未來實驗室」帶來的效率提升所驅動。我們也吸收了較高的運輸費用與燃油附加費的影響。毛利率擴張仍是我們的重點關注領域;我們很高興看到在此指標上的努力已開始產生成果。

  • Total operating expenses in the quarter were $101.6 million, a decrease of 3% from the prior year period adjusted for a large nonrecurring impairment expense that we recognized in the second quarter of 2025. As we stated previously, while we continue to invest in sales and R&D to drive higher clinical test volumes and AUP, we plan to offset these investments with improved G&A leverage, which we expect will continue to decline as a percent of revenue. This is exactly what we delivered in Q2.

    本季總營業費用為 1.016 億美元;若排除我們在 2025 年第二季認列的一筆大型一次性減損費用,則較去年同期下降 3%。如先前所述,雖然我們持續投資於銷售與研發以推動更高的臨床檢測量與 AUP,但我們計畫透過提升 G&A(一般及行政)槓桿來抵銷這些投資;我們預期 G&A 佔營收比重將持續下降。這正是我們在第二季所交出的成果。

  • Sales and marketing spending increased $3.2 million or 13%, reflecting continued investment in the commercial organization. Research and development spending increased $1.7 million or 19%, supporting our pipeline priorities.

    銷售與行銷支出增加 320 萬美元(年增 13%),反映我們持續投資於商業組織。研發支出增加 170 萬美元(年增 19%),以支持我們的產品管線優先事項。

  • These increases were more than offset by an $8 million decline in general and administrative expenses, which was driven by continued expense discipline across the organization and a step down from one-time expenses incurred in the second quarter of '25.

    上述增加的支出,已被一般及行政費用減少 800 萬美元所抵銷;該下降主要來自全組織持續的費用紀律,以及相較於 2025 年第二季所發生的一次性費用有所回落。

  • Adjusted EBITDA was $14.4 million, up 36% year over year, representing revenue pull-through of approximately 19%, driven by the gross margin expansion and operating expense discipline that we just discussed.

    調整後 EBITDA 為 1,440 萬美元,年增 36%;營收拉動效應(pull-through)約為 19%,主要由我們剛才討論的毛利率擴張與營業費用紀律所驅動。

  • Turning now to our balance sheet. During the quarter, we successfully raised $316 million through a convertible senior notes offering due in 2032 and used a portion of the proceeds to retire $276 million of our existing convertible senior notes due in 2028. We also entered into capped call transactions and repurchased shares of our common stock for an aggregate purchase price of $25 million intended to reduce potential dilution.

    接著看資產負債表。本季我們成功透過 2032 年到期的可轉換優先票據發行募集 3.16 億美元,並使用部分募得資金償還 2.76 億美元、原本於 2028 年到期的既有可轉換優先票據。我們也進行了 capped call 交易,並以合計 2,500 萬美元回購普通股,旨在降低潛在稀釋。

  • We generated approximately $20 million in operating cash in this quarter and invested $8 million in capital purchases, including our investment in NovaSeq X to move LBx on this platform. Also, as we announced last week, we reached a settlement with the DOJ regarding a legacy self-disclosed matter. As part of the settlement, we paid roughly $10 million. And while this has already been reserved for in our financials, this will impact our cash from operations in the third quarter.

    本季我們產生約 2,000 萬美元的營運現金流,並投入 800 萬美元於資本性採購,包括我們投資 NovaSeq X 以將 LBx 轉移至該平台。此外,如我們上週所公告,我們就一項過往自行揭露的歷史案件與美國司法部(DOJ)達成和解。作為和解的一部分,我們支付約 1,000 萬美元。雖然此金額已在我們的財務報表中提列準備,但將在第三季影響我們的營運現金流。

  • We ended the quarter at a healthy $145.5 million in cash and cash equivalents while having strengthened our capital structure and extended our convert debt maturity from 2028 to 2032.

    我們在本季末持有健康的1.455億美元現金及約當現金,同時強化了資本結構,並將可轉換債務到期日由2028年延長至2032年。

  • Turning now to our 2026 guidance. Considering our strong second quarter revenue performance, we are raising our full year '26 revenue guidance to a range of $802 million to $806 million, up from $797 million to $803 million discussed previously.

    接下來談我們對2026年的指引。考量我們第二季強勁的營收表現,我們將2026全年營收指引上調至8.02億至8.06億美元區間,高於先前討論的7.97億至8.03億美元。

  • The key assumptions underlying the midpoint of our revised revenue guidance are as follows: first, we expect our clinical business to grow in low teens for the full year, driven by the continued strength in our NGS business. We expect our NGS business to grow in mid-20%s versus our prior estimate of low 20% growth.

    我們上修後營收指引中位數所依據的主要假設如下:第一,我們預期臨床業務全年將以十幾%的低段成長,主要由NGS業務持續強勁所帶動。我們預期NGS業務成長將達到20%中段,較先前預估的20%低段成長更高。

  • Second, no change in RaDaR ST or PanTracer Liquid revenue assumptions, both of which remain in the mid-single-digit millions.

    第二,RaDaR ST或PanTracer Liquid的營收假設不變,兩者仍維持在數百萬美元的中個位數水準。

  • Finally, we now expect our nonclinical business to be down high single digits year over year in '26 as compared to our earlier guidance of down low to mid-single digits.

    最後,我們現在預期2026年非臨床業務營收將年減高個位數,相較於先前指引為年減低至中個位數。

  • Regarding the quarterly cadence, we suggest modeling approximately 10% revenue growth in the third quarter, up from 9% to 10% discussed previously and above 10% in the fourth quarter of 2026. For gross margin, we anticipate approximately 100 to 150 basis points of improvement for the full year 2026.

    就季度節奏而言,我們建議第三季以約10%的營收成長來建模,高於先前討論的9%至10%,並預期2026年第四季成長將高於10%。就毛利率而言,我們預期2026全年將改善約100至150個基點。

  • We're also raising our full year '26 adjusted EBITDA guidance to a range of $56 million to $58 million versus $55 million to $57 million previously, representing year-over-year growth of over 30% at the midpoint. We are targeting adjusted EBITDA to grow in the low 30%s year over year in the third and the fourth quarter.

    我們也將2026全年調整後EBITDA指引上調至5,600萬至5,800萬美元區間,先前為5,500萬至5,700萬美元;以中位數計算,代表年增超過30%。我們目標是在第三季與第四季,調整後EBITDA年增維持在30%低段。

  • With that, let me turn the call over to Tony.

    接下來我把電話交給Tony。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thanks, Abhishek. In closing, we view this as a very strong quarter for NeoGenomics as total revenue increased 11%, clinical revenue increased 14%, and we expanded our margins. We have achieved and remain on track for key catalysts we outlined at the beginning of this year across new product launches, reimbursement, and sales force expansion. These set us up well to further deliver consistent results and drive durable and profitable revenue growth. I'd like to thank you for your continued interest in NeoGenomics.

    謝謝你,Abhishek。總結來說,我們認為這對NeoGenomics而言是非常強勁的一季:總營收成長11%,臨床營收成長14%,且我們擴大了利潤率。我們已達成並仍按計畫推進今年年初所提出的關鍵催化劑,包括新產品上市、給付(reimbursement)以及銷售團隊擴編。這些讓我們具備良好基礎,得以持續交出穩健成果,並推動具持久性且具獲利性的營收成長。感謝各位持續關注NeoGenomics。

  • And operator, this concludes our prepared remarks, so please open the line for questions.

    接線員,以上為我們的預先準備發言,請開放提問。

  • Operator

    Operator

  • (Operator Instructions) David Westenberg, Piper Sandler.

    (接線員指示) David Westenberg,Piper Sandler。

  • David Westenberg - Analyst

    David Westenberg - Analyst

  • Thank you for taking the question and great job on the quarter here. So I wanted to get into NGS growth. It was 26% again in the quarter. You have really liquid in the back half of the year really to get it supposed to take off. You're getting all these MRD indications. At the same time, you probably do have some tough comps. So how should we think about the back half of the year? Is there conservatism here in the NGS guide? What are you leaving room for in the guide in NGS right now in the back half of the year? And I have one more.

    謝謝讓我提問,本季表現做得很好。我想深入談談NGS的成長。本季又是26%。你們在今年下半年有很多液體(檢測)相關動能,應該會真正起飛。你們也拿到這些MRD適應症。同時,你們可能也會面臨一些較嚴峻的比較基期。那我們該如何看待下半年?NGS指引是否偏保守?你們在目前NGS下半年指引中,預留了哪些空間?我還有一個問題。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Hey, Dave, it's Tony. Thanks very much for the question. I'll kick us off on the NGS bigger picture and then, Abhishek, you can also go into the guide implications in the second half of the year on NGS. So Dave, our view of this is we think we have a very durable position with NGS now. As you said, we exited '25 at about a 22% growth, and that's why we guided below 20%s.

    嗨,Dave,我是Tony。非常感謝你的提問。我先從NGS的大方向談起,接著Abhishek也可以補充下半年NGS指引的含意。Dave,我們的看法是:我們現在在NGS上擁有非常具持久性的地位。如你所說,我們在2025年結束時約為22%的成長,因此我們當時給出的指引是低於20%多的區間。

  • Now in the first quarter of '26, we did 26% in Q1 and we matched that again in Q2 at 26%, that's why we're raising the guide to the mid-20%s now. And if you break down that Q2, you look at that 26%, like 14% was volume and 12% was AUP, which about two-thirds of that was mixed.

    而在2026年第一季,我們Q1做到了26%,Q2也同樣是26%,因此我們現在把指引上調到20%中段。若拆解Q2的26%成長,大約14%來自量(volume),12%來自AUP,其中約三分之二是組合(mix)因素。

  • And so we start to look at this at the macro level across a blended portfolio, that 14% looks pretty good to us because remember, we're driving an intentional shift from single panels to large panels. And as Warren said, that large panel is at 20% growth.

    因此,當我們以宏觀角度檢視整體組合式產品組合時,這個14%在我們看來相當不錯,因為請記得,我們正有意推動從單一panel轉向大型panel。而如Warren所說,大型panel的成長率為20%。

  • And we see strong growth in heme, the five products growing at 30%. So we see our position going into the second half of the year as one of a position of strength. We do think there's opportunities for us in the portfolio and equally well, we think it's durable.

    我們也看到血液腫瘤(heme)領域強勁成長,五項產品成長達30%。因此我們認為,進入下半年時,我們處於一個強勢的位置。我們確實認為在產品組合中仍有機會,同時也認為這樣的成長具持久性。

  • So with that, Abhishek, anything about key highlights on the guidance that Dave was asking about?

    所以,Abhishek,針對Dave剛才問到的指引重點,你有什麼要補充的嗎?

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Yeah. I think you have it covered well, Tony. So for the second half, we are basically raising that, okay, our NGS revenue growth for the full year is going to be now in the mid-20%s as compared to the low 20%s that we had guided for previously. And this is predicated upon our strong performance that we have seen in the first half, particularly the larger panels that Warren alluded to in his prepared remarks. Those have been growing above 20%.

    有。我想你已經講得很完整了,Tony。就下半年而言,我們基本上是把NGS全年營收成長上調到20%中段,相較於先前指引的20%低段。這是基於我們在上半年看到的強勁表現,特別是Warren在預先準備發言中提到的較大型panel。那些的成長率已高於20%。

  • David Westenberg - Analyst

    David Westenberg - Analyst

  • Got it --

    了解--

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • And I think that just for the sake of clarity though, MRD is not included in NGS numbers. NGS is like-for-like. MRD is reported separately. It will be included in clinical.

    另外我想為了釐清一點,MRD不包含在NGS數字中。NGS是同口徑(like-for-like)。MRD會另外單獨揭露。它會被納入臨床(clinical)。

  • David Westenberg - Analyst

    David Westenberg - Analyst

  • Great. Thank you for that clarification. And then, Tony, can you give us a little bit more color on what's happening in biopharma? I mean, I think everyone had it negative at high single-digits. But you said you spend time working on it.

    很好。謝謝你釐清。接著,Tony,你能否多分享一些biopharma那邊的情況?我的意思是,我想大家原本都預期會是高個位數的負成長。但你提到你花了時間在處理這件事。

  • It is only 6% of revenue. Can you remind us the need for this business overall? Just it is such a small portion of the portfolio. You almost wonder like nobody owns Neo for its pharma services. So anyway, if you could just remind us the importance of it and what you're going to be doing there, what's going on. Thank you.

    它只占營收的6%。你能提醒我們這項業務對整體而言的必要性嗎?它在產品組合中占比這麼小。你幾乎會覺得沒有人是因為Neo的藥廠服務而持有Neo。所以無論如何,如果你能提醒我們它的重要性,以及你們接下來會怎麼做、那邊到底發生了什麼。謝謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Yeah, sure, Dave. Again, maybe just to kick things off, in the quarter, we were very pleased with a lot of performance across the business, primarily on the clinical side with revenue, volumes, AUP, there was a lot to be excited about. But an area where we just didn't hit our own expectations was on the nonclinical pharma side primarily.

    好的,當然可以,Dave。再說一次,也許先開個頭:本季我們對於業務多個面向的表現都非常滿意,主要是在臨床端,包括營收、量、AUP等,有很多令人振奮之處。但有一個我們沒有達到自身預期的領域,主要是在非臨床的藥廠端。

  • And what I would tell you, Dave, that we liked in the quarter, bookings were up significantly in Q2. So the new team that's in place is driving and delivering what we expected from the bookings. We just didn't see the same pull-through rate that we saw historically from the 2025 bookings that were in place. So that's what led to the slight downturn in expectations for the year.

    我想跟你說的是,Dave,我們在本季喜歡的一點是,Q2 的訂單(bookings)顯著成長。因此,目前到位的新團隊正在推動並交付我們對訂單所預期的成果。只是我們沒有看到與過往相比、從既有的 2025 年訂單所帶來的同等轉換率(pull-through rate)。所以這就是導致我們對全年預期略為下修的原因。

  • We're still confident that we can get this back to growth. And then, the bigger question as to why, well, we still believe that there's opportunity here for us to leverage that pharma experience. It gives us earlier access for some of our key products. We stay at the front edge of what's happening in the marketplace. So there's a lot of reasons to want to stay engaged.

    我們仍然有信心可以讓它回到成長軌道。至於更大的問題是為什麼——我們仍然相信,這裡有機會讓我們運用在製藥(pharma)端的經驗。這能讓我們對某些關鍵產品更早取得市場切入(earlier access)。我們也能站在市場動態的最前沿。因此,有很多理由讓我們希望持續投入並保持參與。

  • And if you look at how our portfolio will emerge over time with whole genome in both MRD and in heme, we think that there's going to be opportunity there. So we think it's important to not lose our focus in clinical, but we still think there's opportunity there if we can right this thing going into 2027. Hope that helps.

    而且如果你看我們的產品組合隨時間的演進,包含在 MRD 與血液腫瘤(heme)領域的全基因組(whole genome),我們認為那裡會有機會。所以我們認為重要的是不要在臨床端失去焦點,但如果我們能在邁向 2027 年之前把這件事扭轉過來,我們仍然認為那裡有機會。希望這有幫助。

  • David Westenberg - Analyst

    David Westenberg - Analyst

  • Yeah. Thank you.

    好的。謝謝。

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • And I'll just add to what -- just taking the conversation maybe one level higher here, given the fact that pharma is 5% of our business, you're talking about a $10 million business out of $200 million of revenue. Now even $0.5 million can swing the percent by 5 points, Dave, right? So basically, you're talking about now $0.5 million impact on a $200 million business, which could be like a rounding adjustment for the overall business.

    我再補充一下——把討論拉高一個層次來看,鑑於製藥端只占我們業務的 5%,你談的是在 2 億美元營收中約 1,000 萬美元的業務。而且就算是 50 萬美元的變動,也可能讓百分比上下擺動 5 個百分點,Dave,對吧?所以基本上,你談的是 2 億美元業務中 50 萬美元的影響,對整體業務而言可能只是四捨五入的調整。

  • So I just want to make sure that from the focus standpoint, it's basically our clinical business. And on the pharma, yes, of course, we did not meet the expectation, but such a small portion of our overall portfolio.

    所以我只是想確認,從聚焦的角度來看,我們的重點基本上是在臨床業務。至於製藥端,是的,當然我們沒有達到預期,但它在我們整體產品組合中只占很小一部分。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thanks, Dave.

    謝謝你,Dave。

  • Operator

    Operator

  • Puneet Souda, Leerink Partners.

    Puneet Souda,Leerink Partners。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Yeah. Hi, guys. Thanks for the questions here. And following up on that, again, this business, as you pointed out, non-clinical business, pharma business is 5% overall has been under pressure. Can you talk a little bit about how core is this to NeoGenomics ultimately? Obviously, you're doing well on the clinical side and on the AUP and other product launches as well. So maybe just talk to us about how core is this and what are the plans ahead? Thank you.

    好的。嗨,各位。謝謝回答問題。延續剛才的話題,正如你們指出的,這塊業務——非臨床業務、製藥業務——整體占比 5%,一直承受壓力。你們能否談談,從長期來看,這對 NeoGenomics 到底有多核心?顯然你們在臨床端表現很好,AUP 以及其他產品上市也進展不錯。所以請跟我們談談這塊有多核心,以及接下來的計畫是什麼?謝謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Yeah, Puneet, again, I'll kick us off. I would say, what is core to us? Our clinical business. That's what's core to us. That's what's going to drive our performance and our growth.

    好的,Puneet,我再一次先開頭。我會說,什麼對我們是核心?我們的臨床業務。那才是我們的核心。那將驅動我們的表現與成長。

  • I look at pharma as more opportunistic. One that we can leverage from our R&D perspective, one that we can get early market access, one that will probably suit our emerging portfolio a lot better than it suited our existing portfolio.

    我把製藥端視為更偏機會型(opportunistic)。它能讓我們從研發(R&D)的角度加以運用,讓我們更早取得市場切入,也可能比起我們現有的產品組合,更適合我們正在成形的新產品組合。

  • I do not consider it in waiting to be anywhere near of strategic importance as we see the clinical side of the business, but it's an area that we can leverage overtime and one that we want to just make sure we get correct moving into 2027.

    我不認為它在可預見的時間內會接近我們對臨床業務所賦予的策略重要性,但它是我們可以隨時間加以運用的一個領域;同時我們也希望確保在邁向 2027 年時把它做對。

  • Warren, you want to add anything else?

    Warren,你還想補充什麼嗎?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Building on that, I think one of the things you would have seen within the OpEx was increased investment from R&D perspective. We're becoming increasingly excited about the products that will come to market, more of them, more cutting edge the WGS that Tony had spoken about.

    在此基礎上,我想你們在營運費用(OpEx)中看到的一點,是我們從研發角度增加了投資。我們對即將上市的產品越來越感到興奮——產品更多、也更前沿,包括 Tony 提到的全基因組定序(WGS)。

  • We feel it's imperative that we have access into pharma to get early readouts in terms of how those products perform, get some early clinical studies, make adjustments, et cetera, before we actually bring those products to market from a clinical perspective once reimbursement is available. So we see it as an enabler of our clinical business, but not an area that we're going to be making any meaningful investments in.

    我們認為,必須能進入製藥端,才能更早取得這些產品表現的初步讀數(readouts),做一些早期臨床研究,並在我們真正把產品以臨床商業化方式推向市場(在可取得給付/報銷 reimbursement 之後)之前,進行調整等等。所以我們把它視為臨床業務的促成因素(enabler),但不是我們會投入任何具實質意義資本/資源的領域。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Okay. That's helpful. And then just a quick follow-up on your AUP came in really strong versus last quarter. Again, congrats on that volume ahead of us, too. But maybe just on the AUP side, look, it's driven by mix shift. I appreciate that.

    好的。這很有幫助。接著快速追問一下,你們的 AUP 相較上一季表現非常強勁。也再次恭喜,前方的量也很不錯。不過就 AUP 來說,我知道主要是由組合轉移(mix shift)所驅動。我理解。

  • But given the competition dynamics in the marketplace and what's the level of sustainability for how sustainable is this AUP growth? How should we think about -- or the the mix of AUP versus volume growth for clinical in the next two quarters? And if you can provide anything on '27, that would be helpful, too. Thank you.

    但考量市場上的競爭態勢,這種 AUP 成長的可持續性有多高?未來兩季臨床端的 AUP 成長與量(volume)成長的組合,我們應該怎麼看?如果你們也能提供一些對 2027 年的看法,也會很有幫助。謝謝。

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Sure. Quite a few questions unloaded, Puneet. Let me take a shot at it. So on the AUP, the 12% growth, I would say that there have been like two pieces to it. The first piece is, of course, the RCM, the true RCM initiative, which is basically how you're able to drive the pricing gains through the managed care, through the pull-through, so on and so forth, and the price increases. So that's the first component.

    當然。Puneet,你一次丟了不少問題。我試著回答。關於 AUP 的 12% 成長,我會說大致有兩個部分。第一部分當然是 RCM,也就是真正的 RCM 計畫,基本上是你如何透過受管理醫療(managed care)、轉換(pull-through)等等,以及調價,來推動價格提升。這是第一個構成。

  • The second component is, as we continuously seeing this mix shift towards the high-value testing -- and again, that's depending on the NGS revenue growth that we are seeing, which has been very strong. And as we know that the NGS AUP is much more higher, compared to the rest of our portfolio.

    第二個構成是,我們持續看到組合往高價值檢測(high-value testing)轉移——而這取決於我們看到的 NGS 營收成長,這一直非常強勁。而且我們知道,NGS 的 AUP 相較於我們產品組合的其他部分要高得多。

  • Given the fact we believe that the NGS volume growth is pretty durable, we believe that we will continue to see this AUP benefit in the future quarters to come. That basically gives us a comfort.

    鑑於我們相信 NGS 的量成長相當具韌性(pretty durable),我們相信未來幾季仍會持續看到這樣的 AUP 受益。這基本上讓我們感到安心。

  • And at the same time, I would say that there is a meaningful runway left for us on the RCM side as well because still there are opportunities for us to improve the pricing on the contracts that we currently have got. The good news is that we have 300 contracts.

    同時我也會說,在 RCM 方面我們仍有相當大的跑道(runway),因為我們仍有機會改善目前合約的定價。好消息是我們有 300 份合約。

  • And just to give you an example that this past quarter, we actually were able to increase the contractual price with one of the top 10 national payers. So the point being that there is still more runway left on our RCM improvement, that gives us the belief that this is durable.

    舉例來說,在上一季,我們實際上成功把其中一家全國前十大付款方(national payer)的合約價格提高。所以重點是,我們在 RCM 改善上仍有更多跑道,這讓我們相信這是可持續的。

  • Now from the Q3 and Q4 standpoint, what I'm suggesting that we will still have a more heavy AUP-led growth in the Q3 and Q4. Q3, I would suggest that we should be looking at the volume growth at about 1, 1.5 points, and that is primarily because of the same dynamics that we have discussed in the past that this high-volume, low-value contract that we exited, it basically peaked in Q3 '25.

    至於 Q3 和 Q4,我的看法是 Q3、Q4 仍會是以 AUP 帶動的成長占比較高。Q3 我會建議把量成長看在大約 1 到 1.5 個百分點,主要是因為我們過去討論過的同樣動態:我們退出的那個「高量、低價值」合約,它在 2025 年 Q3 達到高峰。

  • So you will still see the most revenue growth in the clinical would come from the AUP growth, but the mix will start to shift in 2027, where we feel that the volume growth is going to be mid-single digit or so what we used to see previously. And accordingly, you will start to see some softening on the AUP growth numbers as well.

    因此,你仍會看到臨床端最大的營收成長來自 AUP 的成長,但產品組合將在 2027 年開始轉移;我們認為屆時量的成長將會是中個位數左右,或大致回到我們先前看到的水準。相應地,你也會開始看到 AUP 成長數字出現一些趨緩。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • That's great. Very helpful context. Thank you.

    太好了。這些背景資訊非常有幫助。謝謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thanks, Puneet.

    謝謝你,Puneet。

  • Operator

    Operator

  • Tycho Peterson, Jefferies.

    Tycho Peterson,Jefferies。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Hey. Thanks. Just think a little bit about RaDaR, the third indication here. Maybe just, first of all, are there milestones we should be tracking over the next 12 months as you expand the indication set? And how do you think about the opportunity here in terms of increased patient eligibility versus improved testing cadence?

    嗨。謝謝。想請你談談 RaDaR,這裡的第三個適應症。也許先問,未來 12 個月在你們擴大適應症組合的過程中,有哪些里程碑是我們應該追蹤的?另外,你們如何看待這裡的機會:是來自可納入的病患資格增加,還是來自檢測頻率(cadence)提升?

  • And I don't think you're changing your TAM assumptions. You're saying now over 40%. I think you said 45% previously when you have four indications. So I just want to make sure the TAM assumptions haven't changed either.

    而且我不認為你們有改變 TAM 的假設。你們現在說超過 40%。我記得你之前在有四個適應症時說過 45%。所以我只是想確認 TAM 的假設也沒有改變。

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Tycho, let me take that.

    Tycho,這題我來回答。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Yes, please.

    好的,麻煩。

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • I think we're really excited about the fact that we've added a third indication. And we still believe that the two that we spoke about previously, we should receive reimbursement before the -- at the end of the year. And we expect somewhere in the first half -- latter part of the first half of 2027 for this third indication. Again, thinking about the 12-month review cycle is what we're working on there.

    我想我們對新增第三個適應症這件事非常振奮。而且我們仍然相信,先前提到的那兩個適應症,我們應該會在——在年底之前取得給付。至於第三個適應症,我們預期大概會在 2027 年上半年後段的某個時間點。同樣地,我們目前是以 12 個月的審查週期來推進這件事。

  • And again, we've just -- we're in the process of making some commercial investments in anticipation of those additional indications becoming available and being able to expand the indications that we actively promote. And again, it's something, as I said in my prepared remarks, we continue to evaluate as new products and new reimbursement become available.

    另外,我們也正在進行一些商業化投資,為這些額外適應症可用、以及我們能擴大主動推廣的適應症範圍做準備。而且如同我在事先準備的發言中提到的,隨著新產品與新的給付逐步到位,我們會持續評估。

  • So I would expect that we would further invest in our oncology sales team moving forward in 2027 and beyond. I think from a TAM perspective, the 40% if all five are approved, that gives us access to the 40%, that is meaningfully up from where we were with just the prior two indications. So I'm not sure where that 45% came from. I don't believe that's something we publicly shared before.

    所以我預期,到了 2027 年及之後,我們會進一步投資在腫瘤銷售團隊上。就 TAM 的角度來看,如果五個適應症都獲核准,40% 代表我們可觸及的市場占比達到 40%,相較於先前只有兩個適應症時,這是顯著提升。所以我不確定 45% 是從哪裡來的。我不認為那是我們之前對外公開分享過的數字。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay. Yeah. The 45% when you have four indications. But one for Abhishek then, just thinking about the gives and takes on OpEx. So you're bringing up SG&A with new hires, R&D with the innovation funnel. And I know you've talked about reductions to G&A over the next 12 to 24 months.

    了解。是的。我指的是在你們有四個適應症時的 45%。那接著問 Abhishek 一題,關於營運費用(OpEx)的取捨。你們因為新聘人員而提高 SG&A,因為創新漏斗而提高 R&D。而我也知道你們談過在未來 12 到 24 個月降低 G&A。

  • So maybe just talk about where you'll get the leverage on G&A, and is the algorithm of a 250 to 300 basis points operating expansion still viable under the new framework?

    所以能否談談你們會從哪些地方在 G&A 上取得槓桿效益?以及在新的架構下,營業利益率擴張 250 到 300 個基點的模型是否仍然可行?

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • No, that's a great question. And in fact, probably one of the focus areas for us is to drive the operating leverage in the G&A, Tycho. When we look at the numbers, we feel that our G&A spend as compared to some of our peer groups is definitely higher. And when I look at the G&A only, it was like, what, 38% or so as a percent of revenue in '25. We are targeting low 30%s this year.

    不,這是個很好的問題。事實上,Tycho,推動 G&A 的營運槓桿可能是我們的重點領域之一。當我們看這些數字時,我們覺得相較於一些同業,我們的 G&A 支出確實偏高。而且如果只看 G&A,2025 年大概是營收的 38% 左右。我們今年的目標是壓到 30% 出頭。

  • And we hope that the number, the percent on the G&A will continue to reduce further in the outer years, perhaps lower than 30% in 2027.

    我們也希望在更外圍的年度,G&A 的占比能持續再下降,或許在 2027 年降到 30% 以下。

  • So given the fact that G&A, we do have more opportunities as we start to get the benefit of some of the work that the team has been doing, we would basically have the opportunity to invest back into our sales organization and in advancing our pipeline initiatives through the R&D programs. Those are -- this is how we basically see as to how this whole thing is going to pan out.

    因此,鑑於在 G&A 上我們確實有更多機會,隨著團隊正在做的一些工作開始帶來效益,我們基本上就有機會把資源再投入到銷售組織,以及透過研發計畫推進我們的產品線(pipeline)倡議。這些——這就是我們對整體發展走向的看法。

  • And we'll see as to, okay, what is the right level of investment because we do think that there are a lot of growth opportunities, and we just want to make sure that we are balancing the need to put the money back for the growth and then dropping to the bottom line.

    而我們也會再觀察,什麼才是合適的投資水準,因為我們確實認為有很多成長機會;我們只是想確保在把資金回投到成長、以及讓獲利落到底線之間取得平衡。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Tycho, the only thing I would add to Abhishek's comments is that our focus, while it's on the G&A area right now, we think there are other efficiencies across the enterprise that we're going to be able to drive rather significantly, and we'll probably do a better job of highlighting those for you and your colleagues going into 2027.

    Tycho,我唯一想補充 Abhishek 的是:雖然我們目前的焦點放在 G&A,但我們認為在整個企業範圍內還有其他效率可以相當顯著地推動;我們可能會在邁向 2027 年的過程中,更好地向你和你的同事說明這些。

  • And when you start to really look at some of the work that Warren is doing in the Lab of the Future and his teams, there's ample opportunity for us to drive efficiencies that we think can help the bottom line performance as well as offset some of the investments we want to make in sales and the development side of the business.

    而當你開始仔細看 Warren 在「未來實驗室」(Lab of the Future)以及他團隊所做的一些工作時,我們有充足的機會去推動效率提升;我們認為這不僅能改善底線表現,也能抵銷我們想在銷售端與業務開發端所做的一些投資。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay. And the last one, just you submitted comments to CMS on prior authorization. I'm just curious how we think about any progress there.

    了解。最後一題,你們就事前授權(prior authorization)向 CMS 提交了意見。我只是好奇,我們該如何看待那邊的任何進展。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • On CMS?

    關於 CMS?

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Yeah, just on the challenges around prior authorizations. I mean, is that something we should see some traction on?

    對,就是關於事前授權相關的挑戰。我的意思是,這會是我們應該期待看到一些進展的事情嗎?

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Well, we looked at all the initiatives that are being discussed at this point, Tycho, PAMA, CRASH, ACA, all of these various issues. We continue to study all of them because, as you know, there's multiple potential iterations of these things.

    嗯,Tycho,我們檢視了目前正在討論的所有倡議:PAMA、CRASH、ACA,以及各種不同議題。我們會持續研究它們,因為如你所知,這些事情可能有多種不同的版本與演變。

  • But our view hasn't really fundamentally changed that much. We've assessed them. We continue to work with ACLA, and we look at our portfolio, and we don't see anything here that would be a significant impact to our business in 2027. So we'll continue to stay close to it. We'll work with ACLA, but it's not something we're anticipating to be significant.

    但我們的看法並沒有在根本上改變太多。我們已經評估過。我們持續與 ACLA 合作,也檢視我們的產品組合;我們沒有看到任何會在 2027 年對我們業務造成重大影響的事項。所以我們會持續密切關注。我們會與 ACLA 合作,但我們不預期它會是重大的影響因素。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay. Thank you.

    了解。謝謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Bill Bonello, Craig-Hallum.

    Bill Bonello,Craig-Hallum。

  • Bill Bonello - Analyst

    Bill Bonello - Analyst

  • Hey. Thanks a lot. I want to revisit one of the questions about the mix shift, but maybe with a longer-term point of view than what happens in the next two quarters. You did mention some of the strong NGS revenue growth coming from legacy customers transitioning, obviously, from targeted panels to CGP, which we see in the ASP.

    嗨。非常感謝。我想再回到其中一個關於組合轉移(mix shift)問題,但可能用更長期的視角,而不是只看接下來兩個季度會發生什麼。你確實提到,一些強勁的 NGS 營收成長來自既有客戶的轉換——顯然是從標靶 panel 轉到 CGP,而我們也在 ASP 上看得到。

  • Can you just give us some sense of maybe how much runway you still have on that front? Not specifically where ASP is going to go, but what percent of your customers maybe aren't using CGP testing right now are still ordering targeted panels, maybe rarely use liquid biopsy? And maybe the same thing on MRD, even though you say that wasn't in the numbers. But just to give us some sense of how long this path can continue.

    你能否讓我們大概了解一下,在這方面你們還有多少「跑道」(runway)?不是要你具體說 ASP 會走到哪裡,而是你們的客戶中,大概有多少比例目前還沒有使用 CGP 檢測、仍在下單標靶 panel,或是很少使用液體活檢?另外 MRD 也是同樣的問題,儘管你說那不在這些數字裡。但只是想讓我們對這條路徑還能持續多久有個概念。

  • And then just part two of that would be to the extent that you are seeing competitive takeaways, maybe you could talk about what's driving that.

    然後第二部分是,就您所看到的競爭性搶單(competitive takeaways)的程度而言,或許您可以談談是什麼在驅動這些情況。

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Thanks, Bill. I'll take that question. I think maybe before I talk specifically about NGS, the opportunity for mix shift does not only exist within NGS. We have a unique opportunity because of our broad portfolio, and we see mix shift happening across other modalities as well. It's probably most notable, though, within NGS and exactly what you just articulated, targeted panels moving to CGP, et cetera. So yeah, I'd say the runway is still robust.

    謝謝,Bill。我來回答這個問題。我想在我特別談NGS之前,組合轉移(mix shift)的機會不只存在於NGS之內。由於我們產品組合很廣,我們有一個獨特的機會,而且我們也看到在其他檢測/技術模態(modalities)上同樣在發生組合轉移。不過最顯著的可能還是在NGS內部,正如你剛才所說的,標靶panel轉向CGP等等。所以,是的,我會說這條跑道仍然很強勁。

  • We have a fairly broad-based targeted panel portfolio, and it's well covered throughout the community setting because that's what's in guidelines today. And we're proactively targeting customers and driving that shift, and it's part of how we target our commercial organization.

    我們有相當廣泛的標靶panel產品組合,而且在社區醫療場景(community setting)中覆蓋得很好,因為這正是目前指南(guidelines)所建議的內容。我們也在主動鎖定客戶並推動這個轉移,這也是我們商業團隊鎖定目標的一部分。

  • So this is an opportunity that has runway well beyond 2026 and probably into a few years beyond that as well. But again, I want to reiterate, it's not just with regards to NGS, there's other opportunities with other modalities as well.

    因此,這是一個跑道可延伸到2026年之後、甚至可能再往後幾年的機會。但再次強調,這不僅僅是NGS,其他模態也還有其他機會。

  • In terms of competitive -- you asked the question with regards to takeaways. It's pretty difficult to track that specifically. We've learned over the years as we've done life cycle management in terms of how to do it effectively. The key success factor here is workflow integration.

    就競爭面而言——你問的是關於搶單(takeaways)。這其實很難去具體追蹤。多年來,隨著我們在產品生命週期管理(life cycle management)上的推進,我們也學到如何更有效地執行。這裡的關鍵成功因素是工作流程整合(workflow integration)。

  • Bill Bonello - Analyst

    Bill Bonello - Analyst

  • Okay. Thanks a lot.

    好的。非常感謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thanks, Bill.

    謝謝,Bill。

  • Operator

    Operator

  • Dan Brennan, TD Cowen.

    Dan Brennan,TD Cowen。

  • Daniel Brennan - Analyst

    Daniel Brennan - Analyst

  • Great. Thanks for the questions. Congrats on the quarter. Maybe could you just dig in a little on PanTracer Liquid this quarter? Just give us some color on what you're seeing from the launch. I think when you discussed it in the past, I think you've discussed it as really an alternative to solid tumor testing in maybe cases where they don't have access or it's more specific to the tumor type.

    很好。謝謝提問。恭喜本季表現。或許你們能否更深入談談本季的PanTracer Liquid?能否提供一些你們從上市(launch)以來所看到的情況與色彩?我記得你們過去談到它時,將其視為在某些情況下固態腫瘤(solid tumor)檢測的替代方案,例如病患無法取得組織樣本,或更取決於腫瘤類型的情境。

  • But we've heard through oncologists like there's just a lot of ordering liquid and tissue together or using liquid serially later in the cancer types. So I'm just wondering how the early experience is going and what's assumed as you -- is there a potential upside as you maybe see more use of a blood-based test?

    但我們也從腫瘤科醫師那邊聽到,很多情況是液體與組織一起下單,或是在某些癌種後續以序列方式(serially)使用液體檢測。所以我想問的是,早期使用經驗進展如何?以及你們在假設上——隨著血液檢測(blood-based test)使用增加,是否可能帶來上行空間(upside)?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Thanks, Dan. I'll take the question. So first and foremost, let's say, again, part of the liquid strategy was to round out our PanTracer family. And we're seeing category growth, very, very robust category growth overall and liquid is a contributor of that growth as well.

    謝謝,Dan。我來回答。首先再說一次,液體策略的一部分是完善我們的PanTracer產品家族。我們看到整體品類(category)成長非常、非常強勁,而液體檢測也是這個成長的貢獻者之一。

  • And we're seeing growth coming through multiple channels. We're certainly market penetration, identifying oncologists within the community that aren't using liquid that are starting to use liquid. That's attractive for us. We're also seeing some share gains as well from certain competitors where we have a strong position within workflow and customers on the heme side as well. So that's working out really, really nicely.

    而且我們看到成長來自多個渠道。我們確實在做市場滲透(market penetration),在社區端找出原本不使用液體檢測、但開始使用液體檢測的腫瘤科醫師。這對我們很有吸引力。同時,我們也看到從某些競爭對手那裡取得一些市佔提升(share gains),因為我們在工作流程上有很強的定位,而且在血液腫瘤(heme)端的客戶也有很好的基礎。所以這進展得非常、非常順利。

  • We started to see an increased attachment rate as well, where we're seeing liquid and solid coming in concurrently. So that increased a little in the second quarter, and we're mid- to high teens percentage rate there as well. So that's also starting to gain traction. And obviously, that's an opportunity where we've now got two high-value tests that have been run on a single patient.

    我們也開始看到搭配率(attachment rate)上升,也就是液體與固態檢測同時送檢。所以第二季這個比例略有提高,目前大約在十幾個百分點的中高段(mid- to high teens)。因此這也開始獲得動能。而且很明顯,這是一個機會,因為我們現在能在同一位病患身上執行兩個高價值(high-value)的檢測。

  • The serial testing question that you actually posed is something we're starting to track and we actually are starting to see some uptick there, although that's still relatively small at this particular point, and we see that as an opportunity.

    你提到的序列檢測(serial testing)問題,我們也開始追蹤,確實開始看到一些上升趨勢,雖然目前規模仍相對小,但我們把它視為一個機會。

  • And naturally, the other big opportunity that we're tapping into is the reflex when on the tissue side of things where we get QNS/TNP, this is a natural opportunity. But this is slotted in nicely within our PanTracer family.

    當然,我們正在切入的另一個重大機會,是在組織端出現QNS/TNP時的反射檢測(reflex),這是很自然的機會。但整體而言,這項產品已很順利地納入我們的PanTracer家族。

  • Daniel Brennan - Analyst

    Daniel Brennan - Analyst

  • Got it. Thanks for that. And then maybe just back to the volumes, which you discussed the pace in the back half. Can you just remind us how much that high-volume, low-value contract was a weight this quarter, what's baked in for the back half of the year because core clinical volumes were a bit lighter what we were thinking [ex-NVS] but I think that's likely because of this factor. So I'm just trying to tease out the drag in Q3 and/or Q4 and when that lapses and what it means? Thank you.

    了解。謝謝你的說明。另外回到你們談到的量(volumes),以及下半年節奏。你能否提醒我們,這一季那個高量、低價值(high-volume, low-value)的合約對量的影響有多大?下半年已經納入(baked in)多少?因為核心臨床量(core clinical volumes)比我們原先想的要輕一些(不含NVS,[ex-NVS]),但我想這很可能就是因為這個因素。所以我想釐清Q3和/或Q4的拖累(drag)有多大、何時會消失(lapses),以及這代表什麼?謝謝。

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Yeah, sure, Dan. So what we had basically said previously that this high-volume, low-value contract made up about 3% to 4% of our volumes in 2025. If you were to take the midpoint, that's almost like 50,000 tests for 2025. And it grew from Q1 to Q2 to Q3 and Q3 was the peak quarter. And then, of course, in the Q4, we had called out that we were exiting from this particular contract.

    好的,當然可以,Dan。我們之前基本上說過,這個高量、低價值合約在2025年約占我們量的3%到4%。如果取中間值,2025年大概接近5萬次檢測。而且它從Q1到Q2到Q3逐季成長,Q3是高峰季度。然後當然在Q4,我們也特別指出我們會退出這個合約。

  • And that's where the compares for the Q3 '26 for us will be the most difficult. And that's the reason why we are calling this particular piece out. Excluding this particular dynamic, we have basically typically been in the mid-single digit on the volume growth, and we would have been pretty similar if we were to adjust for this time.

    因此,對我們而言,2026年Q3的比較基期(compares)會是最困難的。這也是我們為什麼要特別把這一塊拿出來說明。若排除這個因素,我們的量成長通常大致在中個位數(mid-single digit),如果把這個影響調整掉,這次也會相當類似。

  • Daniel Brennan - Analyst

    Daniel Brennan - Analyst

  • Great. Thank you.

    很好。謝謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thanks, Dan.

    謝謝,Dan。

  • Operator

    Operator

  • Subbu Nambi, Guggenheim Securities.

    Subbu Nambi,Guggenheim Securities。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Hey, guys. This is Subbu Nambi. Thank you for taking my question. You guys called out the $8 million in NovaSeq X transition. So I'm curious to know how should we think about CapEx plans into the second half? What's the transition timeline? Any expected gross margin benefit either to this year or next year? How should we think about those things?

    嗨,各位。我是Subbu Nambi。謝謝你們回答我的問題。你們提到NovaSeq X轉換(transition)相關的800萬美元。所以我想了解,我們應該如何看待下半年的資本支出(CapEx)計畫?轉換時程(timeline)是什麼?今年或明年是否預期會有任何毛利率(gross margin)上的好處?我們應該如何看待這些事項?

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • So I can start, and then, of course, I will leave Warren to opine on a few other pieces. So this is basically our first transition to the NovaSeq X on the liquid platform. We are now going to be starting our most important piece, which is the heme transition to the NovaSeq X, which is going to take a few quarters and in the early parts of 2027. So from the gross margin benefit perspective, given the fact that liquid is a very small portion, we are not going to be getting the benefit on the gross margin expansion for this transition as of right now.

    我可以先開始回答,然後當然也會請Warren就其他幾個部分補充看法。這基本上是我們在液體平台(liquid platform)上首次轉換到NovaSeq X。我們現在將開始最重要的一塊,也就是血液腫瘤(heme)轉換到NovaSeq X,這將需要幾個季度,並延伸到2027年初期。因此,從毛利率受益的角度來看,鑑於液體業務占比很小,我們目前不會因這次轉換而在毛利率擴張上獲得明顯好處。

  • And similarly, for the heme movement of the transition, we will start to see the gross margin expansion related to the NovaSeq transition in 2027 latter part. I'll put it this way, if there's something else, Warren that you want to add?

    同樣地,關於過渡期間的 heme 轉移,我們將在 2027 年後半段開始看到與 NovaSeq 轉換相關的毛利率擴張。我這樣說吧,如果還有其他想補充的,Warren?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • No, I think you've hit the key, the salient points there, Abhishek.

    沒有,我想你已經抓到重點了,那些關鍵要點,Abhishek。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Okay. Thank you for that. And, Warren for you, for accounts you are integrated with, but who utilize a competitive MRD test, what percent of those accounts do you feel you'll be able to capture in the indications that are applicable? And how should we think about share win over the course of this year and longer term? I know it's an unfair question, but anything that you could tell us to be helpful.

    好的。謝謝你。另外,Warren,對於那些你們已經整合、但使用競品 MRD 檢測的客戶,你覺得在適用的適應症上,你們能拿下其中多少比例?以及我們應該如何看待今年以及更長期的市占率提升?我知道這問題有點不公平,但你能提供任何有幫助的資訊嗎?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Yeah. I think what's important here is right now, we're only actively promoting RaDaR ST for the two indications that we have reimbursement for, simply because we're trying to manage the cost and profitability dynamic.

    是的。我認為這裡重要的是,目前我們只積極推廣 RaDaR ST 於我們已取得給付的兩個適應症,主要是因為我們在努力管理成本與獲利能力之間的動態。

  • And I do -- I'm very confident of the fact that when we get the additional indications, particularly the two that are due this year, that's going to significantly expand the indications and the TAM that we can address. And I think that's going to allow us to be much more competitive in terms of taking share simply because there is a desire for more of a pan-cancer solution from these larger users.

    而且我——我非常有信心,當我們取得更多適應症,特別是今年預計會拿到的那兩個,將會大幅擴大我們可涵蓋的適應症範圍以及可服務的 TAM(總可服務市場)。我認為這也會讓我們在搶占市占方面更具競爭力,因為這些大型使用者確實希望有更偏向泛癌(pan-cancer)的解決方案。

  • So right now, we're very satisfied with how things are progressing, continue to be laser focused on the two indications that we have. And as we said earlier, two-thirds of the incoming volume is for those indications. And we expect volumes to increase nicely once we get further indications approved later on in the year.

    所以目前我們對進展非常滿意,並持續高度聚焦在我們現有的兩個適應症上。如同我們先前提到的,新增進件量中有三分之二是針對這些適應症。而我們預期在今年稍晚取得更多適應症核准後,量能將會有不錯的成長。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Yeah, Subbu, I guess the only thing I would add to that is we've always maintained that RaDaR ST, we're excited about it because we see it extending our continuum, right, from diagnosis to therapy selection to recurrence monitoring. We look at ourselves as an oncology diagnostics company and not just only an MRD company.

    是的,Subbu,我想我唯一要補充的是,我們一直強調 RaDaR ST 讓我們很興奮,因為我們看到它能延伸我們的連續照護(continuum),對吧,從診斷到治療選擇再到復發監測。我們把自己定位為腫瘤診斷公司,而不只是單純的 MRD 公司。

  • So we're not, at this point, just taking all comers or really casting a really wide net here. We want to get that balance right and our gating factor is going to be the indications. And so as we secure those indications by year-end, that's when we become much more aggressive in reach frequency and messaging.

    因此我們目前並不是要照單全收,或是在這裡撒一張非常大的網。我們希望把平衡拿捏好,而我們的關鍵限制因素會是適應症。所以當我們在年底前拿下這些適應症時,我們就會在觸及頻率與訊息傳遞上變得更積極。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Perfect. Thank you so much, guys.

    太好了。非常感謝各位。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Mason Carrico, Stephens.

    Mason Carrico,Stephens。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Hey, guys. Thanks for taking the questions. A question on pharma. Does returning to growth next year rely on you guys booking additional projects beyond what's in the backlog today? I guess, what's giving you confidence or what visibility do you have into that segment of the business returning to growth next year?

    嗨,各位。謝謝讓我提問。我有一個關於藥廠(pharma)的問題。明年恢復成長是否仰賴你們在目前積壓訂單(backlog)之外再拿到更多專案?也就是說,是什麼讓你們有信心,或你們對該業務板塊明年恢復成長有什麼能見度?

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • So the answer is yes, Mason. It is very much dependent on us continuing to drive incremental bookings. The confidence that we have comes from this quarter. While we didn't hit our revenue goal from the pull-through from '25, the actual bookings were all-time highs for us in Q2, right? So we feel very, very good about what it means for us potentially for '27 and beyond.

    答案是肯定的,Mason。這非常依賴我們持續推動新增訂單(incremental bookings)。我們的信心來自本季。雖然我們沒有達到從 2025 年延伸帶動(pull-through)而來的營收目標,但實際的接單在第二季創下我們的歷史新高,對吧?因此我們對這對 2027 年及之後可能代表的意義感到非常、非常樂觀。

  • But now we just need to execute and pull through the '25 as well as continue to drive the bookings. So it's dependent on bookings. We are seeing bookings increase, and we're going to continue to push hard for that by the end of the year.

    但現在我們需要把執行做好,讓 2025 年的延伸帶動也能落地,同時持續推動接單。所以這取決於接單。我們看到接單正在增加,而且在年底前我們會持續大力推進。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Got it. And then last year, I think you highlighted that Northeast revenue grew maybe 1.5 times faster than the national average. Could you frame up how that segment performed in Q2 and whether that dynamic continued?

    了解。另外,去年我記得你們提到東北地區營收成長可能比全國平均快約 1.5 倍。你能說明一下第二季該區塊表現如何,以及這個趨勢是否延續嗎?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Yeah, I can. So obviously, Q1 indication we put out there. So we're seeing a very similar trend. The only addition that I'll add to that is we're now seeing nice improvement in NGS pull-through as well. So the idea was to get those shorter turnaround time testing first that creates an access point into the customer, then pull through a higher-value testing, and we're now seeing that higher value testing coming through as well.

    可以。所以很明顯地,我們在第一季已經對外提過這個適應症的情況。因此我們看到非常類似的趨勢。我唯一要補充的是,我們現在也看到 NGS 延伸帶動(pull-through)有不錯的改善。原本的想法是先以周轉時間較短的檢測切入,建立進入客戶的切入點,接著帶動更高價值的檢測,而我們現在也看到這些更高價值的檢測開始進來了。

  • So overall, still about 50% above the average, but seeing high-value testing now, too.

    所以整體而言,仍然比平均高約 50%,而且現在也看到高價值檢測的貢獻。

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Thanks. Got it.

    謝謝。了解。

  • Operator

    Operator

  • Mike Matson, Needham.

    Mike Matson,Needham。

  • Michael Matson - Analyst

    Michael Matson - Analyst

  • Yeah. Thanks. So good to see the progress with the Medicare coverage of RaDaR, but I was just curious if you could give us any insight into the process and timing for getting some private insurer coverage of the test.

    是的。謝謝。很高興看到 RaDaR 的 Medicare 覆蓋取得進展,但我想請問你們是否能分享一些關於取得私人保險公司對該檢測給付的流程與時程的看法?

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Yeah, I can take that question, Mike. And as you know that we actually have a fairly wide coverage. For a lot of our tests, we have like 300-plus contracts across the company. Now it's a matter of as to, how do we include some of the newer tests that we are basically launching to the same contract. The good news is that we have a foot in the door and we are able to start to have these conversations.

    好的,Mike,我來回答。如你所知,我們其實已有相當廣泛的覆蓋。對於我們許多檢測,公司層面有 300 份以上的合約。現在的問題在於,我們要如何把一些我們基本上正在推出的新檢測納入同一份合約。好消息是,我們已經有敲門磚,能開始進行這些對話。

  • But at the same time, I'll say that it does take a lot of effort to move the needle in terms of getting first the policy and then the coverage through the contract, and then making sure that you have the right amount of pricing when you're discussing the contract.

    但同時我也要說,要在取得政策(policy)以及透過合約取得覆蓋(coverage)方面推動進展,確實需要投入大量努力,然後還要確保在討論合約時能談到合適的定價水準。

  • I just want to basically highlight that I just said that we actually won one of the top 10 national accounts this particular quarter where the contractual rate was fairly small for our liquid products, and we were able to successfully negotiate a fairly sizable increase in that particular pricing.

    我想特別強調的是,我剛提到我們在本季拿下了一個全國前十大客戶之一;該客戶先前對我們液體產品(liquid products)的合約費率相當低,而我們成功談到相當可觀的價格上調。

  • Now, of course, we'll start to see the impact on our financials as we basically ramp up the volumes, but that's the kind of effort that the team has been doing on the managed care side to drive the policy and the coverage.

    當然,隨著我們逐步拉升量能,我們會開始在財務數字上看到影響;但這就是團隊在商業保險(managed care)端為推動政策與覆蓋所做的那類努力。

  • Michael Matson - Analyst

    Michael Matson - Analyst

  • Okay. Thanks. And then just a quick one on the new convertible or the rollover, I guess, of the convert. So is there any material change in the interest expense related from the refinancing?

    好的。謝謝。另外快速問一題,關於新的可轉債,或我想應該說是可轉債的展期(rollover)。所以這次再融資在利息費用方面有任何重大變化嗎?

  • Abhishek Jain - Chief Financial Officer

    Abhishek Jain - Chief Financial Officer

  • Yeah. There's a little bit of a change in the interest rate. Our new senior notes, the convert senior notes is at 75 basis points. And previously, we had 25 basis points. So there's a 50-basis point differential between the two converts at a high level.

    有。利率有一點變動。我們新的可轉換優先票據(convert senior notes)利率是 75 個基點。先前的是 25 個基點。所以整體來看,兩檔可轉債之間有 50 個基點的差異。

  • Michael Matson - Analyst

    Michael Matson - Analyst

  • Okay. All right. Thank you.

    好的。好。謝謝。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thanks, Mike.

    謝謝,Mike。

  • Operator

    Operator

  • Mark Massaro, BTIG.

    Mark Massaro,BTIG。

  • Mark Massaro - Equity Analyst

    Mark Massaro - Equity Analyst

  • Hey, guys. Thank you for the questions. The first one is on the decision to reorg the commercial team splitting oncology and pathology. Maybe can you just remind us the size of your pathology business relative to the oncology business? And what steps are you taking to ensure that there's continuity in that decision?

    嗨,各位。謝謝讓我提問。第一個問題是關於你們決定重整商業團隊、將腫瘤科與病理拆分。能否請你們提醒一下,病理業務相對於腫瘤業務的規模大概是多少?以及你們採取了哪些措施來確保這項決策的延續性?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Yeah. Thanks, Mark. I'll take that question. So we've wanted to get to this point for quite some time. We just didn't have sufficient scale on oncology sales specialist side of things. So we're actually now with the investments that we made leading up to this quarter and we'll make this quarter, we're about equally balanced, and you could think about 60-plus people in each of those teams now. It's basically given us the scale.

    是的。謝謝你,Mark。我來回答這個問題。我們其實想達到這一步已經有一段時間了。只是先前在腫瘤銷售專員這一端的規模還不夠。所以,隨著我們在本季之前所做的投資,以及本季將持續投入的資源,我們現在兩邊大致上已經相當平衡;你可以把它想成兩個團隊各自都有60多人。這基本上讓我們具備了所需的規模。

  • And we've always had a pathology, what we call TBM, Territory Business Manager and oncology sales specialist, but they rolled up to a generalist manager. And ultimately, we were seeing that generalist manager was struggling with the difference in sales cadence, sales rhythms, et cetera.

    而且我們一直都有病理端(我們稱之為TBM,Territory Business Manager,區域業務經理)以及腫瘤銷售專員,但過去他們都向一位通才型的主管匯報。最終我們看到,那位通才型主管在應對不同的銷售節奏、銷售韻律等差異時確實有些吃力。

  • We've got the pathology business where we're a market leader, looking to protect and grow. We're trying to penetrate oncology with new products where we're not the market leader and in some cases, a later entrant.

    我們的病理業務是市場領導者,目標是守住並擴大成長。而在腫瘤領域,我們正透過新產品來提升滲透率;在那裡我們不是市場領導者,有些情況下甚至是較晚進入的參與者。

  • So there's just two different sales motions, and we felt it would make sense for us to structure the organization through two distinct ecosystems, one for pathology, which is the same sales team and sales management, but also distinct supporting structure.

    因此這是兩種不同的銷售運作方式,我們認為把組織架構建立在兩個清楚區隔的生態系之上是合理的:一個是病理端,維持相同的銷售團隊與銷售管理,但也配套不同的支援架構。

  • So you think about messaging and positioning, it's all targeted towards pathology, the same on the oncology side of things. And I think this is going to sharpen our focus. It's going to improve our targeting. And I think ultimately, it's going to result in better outcomes, which is going to allow us to sustain the growth.

    所以你可以想像在訊息傳遞與定位上,都是針對病理端量身打造;腫瘤端也是同樣的做法。我認為這會讓我們的聚焦更清晰。也會改善我們的目標鎖定。最終我相信會帶來更好的成果,讓我們能夠維持成長。

  • Mark Massaro - Equity Analyst

    Mark Massaro - Equity Analyst

  • Fantastic. And then on the RaDaR ST launch, I recognize it's early days since you launched clinically in February. But can you just give us any sense for perhaps account wins, number of ordering clinicians? Are you encouraged at what you're seeing with breast? Or do you think that you will get a greater uptake when you have expansion of breast?

    太好了。接著關於RaDaR ST的上市,我知道你們在2月才開始臨床推出,現在還算早期。但你們能否分享一下,例如拿下了哪些帳戶、下單的臨床醫師人數等?你們對目前在乳癌方面看到的情況感到鼓舞嗎?或者你們認為等乳癌適應症擴大後,採用率會更高?

  • And how should we think about that business inflecting? Is that something that you think can materially inflect in 2027, or could that take a little bit longer?

    另外,我們應該如何看待這項業務的拐點?你們認為它在2027年就可能出現實質性的拐點,還是可能需要更久一些?

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • So we are seeing -- coming back to account wins, and then we'll talk about the growth and inflection. So we're seeing quite a large array of different types of wins. We certainly are penetrating in the community, which is where we focus.

    我們確實看到——先回到帳戶贏單,然後再談成長與拐點。我們看到相當多元、各種類型的贏單。我們確實正在社區端(community)取得滲透,而那正是我們的重點。

  • And it's a combination of new users of MRD that are coming on board, which came on board through EAP programs and other programs and then also through competitive takeaways in some large group oncology practices as well. So it's pretty a broad array of orders that are coming in. And it's largely because this is a very competitive product.

    這包含了新加入MRD使用的客戶——他們是透過EAP計畫與其他計畫導入的——同時也包含在一些大型團體腫瘤科診所中,從競品那裡爭取回來的訂單。因此進來的訂單型態相當廣泛。而這在很大程度上是因為這是一個競爭力非常強的產品。

  • We have indicated -- we are able to detect down to as low as one part per million. So it's a very, very competitive product. We continue to see great attachment rates, about 30% of incoming RaDaR ST orders actually come in with other testing from Neo, largely NGS, but some auxiliary testing as well. So that's very attractive.

    我們先前也提到——我們能偵測到低至百萬分之一(one part per million)的水平。所以這是一個非常、非常有競爭力的產品。我們持續看到很好的搭售(attachment)比率:大約30%的RaDaR ST新進訂單,會同時搭配Neo的其他檢測,主要是NGS,但也有一些輔助性檢測。因此這非常有吸引力。

  • And we're getting a lot of in indication, two-thirds of the orders today are coming with in indication. And that's really what we're promoting. So I'm optimistic as these additional indications become available and we're able to cover a much larger portion of the TAM that we're going to see acceleration. So we definitely see a meaningful uptick in 2027 and acceleration in the latter part of '27 into '28.

    而且我們也看到很多在適應症範圍內(in indication)的情況;目前約三分之二的訂單是落在適應症範圍內。這也正是我們主打推廣的重點。所以我很樂觀,隨著更多適應症可用、且我們能覆蓋更大比例的TAM(可服務市場總量),我們將看到加速成長。因此我們確實預期在2027年會有明顯的上升,並在2027年後段延續到2028年進一步加速。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • And Mark, we'll be able to better position -- the final part of your question about '27, '28, I think when we see the indication flow and how the year-end closes. So we'll talk '27 in '27, but we'll note that question for next time.

    Mark,至於你問題的最後一部分——關於'27、'28——我想等我們看到適應症推出的節奏,以及年底收官的情況後,我們會更能做出定位與說明。所以我們會在2027年談2027年的事,但我們會把這個問題記下來,下次再回覆。

  • Mark Massaro - Equity Analyst

    Mark Massaro - Equity Analyst

  • That's very helpful. Thanks, guys.

    非常有幫助。謝謝各位。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Thank you.

    謝謝。

  • Warren Stone - President, Chief Operating Officer

    Warren Stone - President, Chief Operating Officer

  • Thank you, Mark.

    謝謝你,Mark。

  • Operator

    Operator

  • We have reached the end of the question-and-answer session, and I will now turn the call over to Tony Zook for closing remarks.

    問答環節到此結束,我現在把電話交給Tony Zook作結語。

  • Tony Zook - Chief Executive Officer, Director

    Tony Zook - Chief Executive Officer, Director

  • Well, first off, again, just like to thank everybody for joining us on the call. I'd also like to thank our roughly 2,400 teammates for their continued hard work and unwavering commitment to our mission.

    好,首先,再次感謝各位參與本次電話會議。我也要感謝我們約2,400位同仁持續的辛勤付出,以及對我們使命堅定不移的承諾。

  • With meaningful progress on our therapy selection and MRD test offerings during the second quarter, I'm excited for the remainder of the year as well as 2027 and beyond, as these high-value tests represent a growing portion of our clinical business. I look forward to our next quarterly update in October and thank you, again, and have a great day.

    隨著我們在第二季於治療選擇與MRD檢測產品上取得實質進展,我也對今年剩餘時間,以及2027年及其後的發展感到振奮,因為這些高價值檢測正占我們臨床業務中愈來愈大的比重。我期待在10月的下一次季度更新;再次謝謝各位,祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.

    今天的會議到此結束,您現在可以掛線。感謝您的參與。